Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
← catalyst calendarNCT06781983 · readout ≤ 620 d
Sponsored by Innate Pharma (industry) · IPH.PA — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
145estimated
Sites
7
Countries
France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-24 | actual | When the study began enrolling |
| Primary completion | Apr 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Solid Tumors
Intervention
- Drug: IPH4502
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability
measured From time of first dose through treatment period, including the follow-up: up to 24 months
Permalink · IPH.PA's whole pipeline · Catalyst calendar · Every registered study · What changed